Advertisement

Intracerebral Interventions for Acute Ischemic Stroke

  • Muneer Eesa
  • Randall T. Higashida
  • Philip M. Meyers
Chapter

Abstract

Two main etiologies of stroke: ischemic vs. hemorrhagic About 85% of strokes are ischemic in nature Ischemic Etiologies include: Arterial thrombotic (i.e., in-situ clot) Embolic Hypoperfusion Venous Thrombotic Hemorrhagic stroke can be classified as: Intra-axial (i.e., intra-ventricular or intra-parenchymal bleed) Extra-axial (i.e., epidural, subdural, or sub-arachnoid bleed)

Keywords

Acute Ischemic Stroke Oxygen Extraction Fraction Fibrinolytic Agent Interventional Neuroradiology Vascular Closure Device 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Bibliography

  1. 1. 
    Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 333:1581–1587, 1995. ® Landmark NINDS trial demonstrating the efficacy of intravenous tPA for acute ischemic stroke when treated within 3 h of onset. Google Scholar
  2. 2. 
    Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008 Sep 25;359(13):1317–29. ® Results of ECASS investigators demonstrating benefit of IV tPA extended to window of 4.5 h. Google Scholar
  3. 3. 
    Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F: Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in acute cerebral thromboembolism. JAMA 282:2003–2011, 1999. ® The Original PROACT II paper, a randomized, controlled, multicenter, open-label clinical trial with blinded follow-up demonstrating improved clinical outcomes in patients with MCA occlusion treated with intra-arterial pro-urokinase within 6 h of onset. PubMedCrossRefGoogle Scholar
  4. 4. 
    Smith WS, Sung G, Starkman S, Saver JL, Kidwell CS, Gobin P, Lutsep HL, Nesbit GM, Grobelny T, Rymer MM, Silverman E, Higashida RT, Budzik RF, Marks MP: Safety and efficacy of mechanical ­embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 36:1432–1438, 2005. ® MERCI trial which led to the FDA approval of a mechanical device for clot retrieval of acute clots in patients ineligible for IV tPA. PubMedCrossRefGoogle Scholar
  5. 5. 
    Bose A, Henkes H, Alfke K, Reith W, Mayer TE, Berlis A, Branca V, Sit SP; Penumbra Phase 1 Stroke Trial Investigators. The Penumbra System: a mechanical device for the treatment of acute stroke due to thromboembolism. AJNR Am J Neuroradiol. 2008 Aug;29(7):1409–13. ® Results of Penumbra system for reducing clot burden in acute stroke due to large vessel occlusive disease. Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Muneer Eesa
    • 1
  • Randall T. Higashida
    • 2
  • Philip M. Meyers
    • 1
  1. 1.Interventional NeuroradiologyColumbia University, College of Physicians and Surgeons, New York Presbyterian HospitalsNew YorkUSA
  2. 2.Interventional NeuroradiologyUniversity of California – San FranciscoSan FranciscoUSA

Personalised recommendations